Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Spinal Fluid
Use
Autoimmune encephalitis and myelitis are increasingly recognized as causes of central nervous system diseases in children and adolescents. Timely diagnosis and identification of specific antibodies can guide treatment strategies and improve outcomes. Disorders associated with antibodies such as NMDA-R, aquaporin-4, CASPR2, GFAP, and others are included in evaluations, providing crucial diagnostic clarity.
Special Instructions
When multiple evaluations are ordered on the same order number, duplicates are canceled. This ensures efficient resource utilization and avoids redundant testing.
Limitations
Negative results do not exclude a diagnosis of autoimmune CNS disorders. Diagnostic accuracy can be influenced by sample quality, timing of sample collection relative to disease course, and technical factors inherent to the assays utilized.
New York Approved
Methodology
Cell-based / Cytometry
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
4 mL
Minimum Volume
2 mL
Container
Sterile vial
Collection Instructions
Preferred collection in vial number 1; any collection vial is acceptable.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |